Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Optimizing transfusion support for patients with MDS

Shuh Ying Tan • 29 Jun 2022
EHA 2022
Myelodysplastic Syndromes

Shuh Ying Tan, MBBS, BMedSci, FRACP, FRCPA, St Vincent’s Hospital Melbourne, Melbourne, Australia, comments on how transfusion support can be optimized for patients with myelodysplastic syndromes (MDS) and factors that should be considered, including the degree of anemia, age of the patient, and comorbidities. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Shuh Ying Tan

1:20
The current standard of care for patients with lower-risk MDS
Shuh Ying Tan • 29 Jun 2022
3:45
The safety and efficacy of KER-050 for the treatment of patients with lower-risk MDS
Shuh Ying Tan • 29 Jun 2022

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals